2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Thyroid Neoplasms
3
Lung Neoplasms
3
Carcinoma, Medullary
3
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Bronchogenic
2
Carcinoma
2
Adenocarcinoma
2
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Glandular and Epithelial
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 2a
1
Locally Advanced Thyroid Gland Carcinoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Diseases
1
Interventions
Trastuzumab
628
Paclitaxel
577
Cyclophosphamide
555
Docetaxel
485
Capecitabine
402
Letrozole
376
Fulvestrant
327
Doxorubicin
294
Carboplatin
279
Tamoxifen
275
Anastrozole
243
exemestane
228
Radiotherapy
218
Epirubicin
211
Bevacizumab
196
palbociclib
189
pertuzumab
186
Vinorelbine
167
Lapatinib
167
Gemcitabine
166
pembrolizumab
162
Surveys and Questionnaires
139
Exercise
136
Magnetic Resonance Spectroscopy
123
Fluorouracil
119
Blood Specimen Collection
118
eribulin
117
Albumin-Bound Paclitaxel
117
Drug Therapy
111
130-nm albumin-bound paclitaxel
111
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
pralsetinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled